Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,521 to 4,540 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Sulopenem vs Ertapenem: deaths from any cause | 2 of 697 0 of 698 | 0.3 points -0.3 to 1.0 | 1,395 | NCT03357614 Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults |
| Sulopenem vs Ertapenem: serious adverse events | 14 of 697 6 of 698 | 1.1 points -0.1 to 2.6 | 1,395 | NCT03357614 Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults |
| Rimegepant vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis | 102 of 135 979 of 1,260 | -2.1 points -10.3 to 4.8 | 1,395 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis | 36 of 135 334 of 1,260 | 0.2 points -7.0 to 8.5 | 1,395 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant vs Triptans: Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis | 132 of 135 1,228 of 1,260 | 0.3 points -3.9 to 2.1 | 1,395 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Month- Primary Analysis | 21 of 135 130 of 1,260 | 5.2 points -0.2 to 12.5 | 1,395 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Primary Analysis | 15 of 135 147 of 1,260 | -0.6 points -5.2 to 6.1 | 1,395 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Rimegepant vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis | 72 of 135 374 of 1,260 | 23.7 points 14.9 to 32.2 | 1,395 | NCT06680206 Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey |
| Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Antiretroviral Therapy (ART) Adherence | 466 of 767 200 of 627 | 28.9 points 23.7 to 33.8 | 1,394 | NCT04571684 Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya |
| Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Number of Participants Receiving Complete PMTCT | 60 of 767 22 of 627 | 4.3 points 1.9 to 6.7 | 1,394 | NCT04571684 Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya |
| Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Antenatal Viral Load (VL) Test Coverage | 330 of 767 137 of 627 | 21.2 points 16.3 to 25.8 | 1,394 | NCT04571684 Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya |
| Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Postnatal Viral Load (VL) Test Coverage | 518 of 767 371 of 627 | 8.4 points 3.3 to 13.4 | 1,394 | NCT04571684 Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya |
| CT Coronary Angiography-based Rapid Rule Out (Group B) vs Traditional Strategy (Group A): deaths from any cause | 2 of 929 3 of 463 | -0.4 points -1.7 to 0.3 | 1,392 | NCT00933400 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS) |
| CT Coronary Angiography-based Rapid Rule Out (Group B) vs Traditional Strategy (Group A): serious adverse events | 0 of 929 2 of 463 | -0.4 points -1.6 to 0.1 | 1,392 | NCT00933400 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS) |
| Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: Objective Response Rate (ORR) | 120 of 694 71 of 697 | 7.1 points 3.5 to 10.7 | 1,391 | NCT00312377 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer |
| Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: Disease Control Rate (DCR) | 413 of 694 380 of 697 | 5.0 points -0.2 to 10.2 | 1,391 | NCT00312377 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer |
| Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events | 263 of 694 232 of 697 | 4.6 points -0.4 to 9.6 | 1,391 | NCT00312377 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer |
| Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Segment Binary Angiographic Restenosis | 102 of 1,062 76 of 328 | -13.6 points -18.7 to -8.9 | 1,390 | NCT00433966 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
| Single Injection of 150 µg SCH 900962/MK-8962 vs Daily 300 IU recFSH: Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event | 5 of 692 6 of 698 | -0.1 points -1.2 to 0.9 | 1,390 | NCT01144416 Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029) |
| Single Injection of 150 µg SCH 900962/MK-8962 vs Daily 300 IU recFSH: Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS) | 5 of 692 10 of 698 | -0.7 points -2.0 to 0.4 | 1,390 | NCT01144416 Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=227"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=227
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03357614-deaths",
"title": "Sulopenem vs Ertapenem: deaths from any cause",
"summary": "2 of 697 against 0 of 698; risk difference 0.3 points, 95% interval -0.3 to 1.0; NCT03357614, Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults",
"record": "/library/comparisons/NCT03357614-deaths",
"nct_id": "NCT03357614",
"kind": "deaths",
"participants": 1395,
"risk_difference": {
"value": 0.0028694404591104736,
"lower": -0.002986632603831936,
"upper": 0.010401377262710282
},
"group_1": "2 of 697",
"group_2": "0 of 698",
"difference": "0.3 points",
"interval": "-0.3 to 1.0",
"trial_title": "Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults"
},
{
"id": "NCT03357614-sae",
"title": "Sulopenem vs Ertapenem: serious adverse events",
"summary": "14 of 697 against 6 of 698; risk difference 1.1 points, 95% interval -0.1 to 2.6; NCT03357614, Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults",
"record": "/library/comparisons/NCT03357614-sae",
"nct_id": "NCT03357614",
"kind": "serious-adverse-events",
"participants": 1395,
"risk_difference": {
"value": 0.011490094675091364,
"lower": -0.0013921540065003,
"upper": 0.02562239127095186
},
"group_1": "14 of 697",
"group_2": "6 of 698",
"difference": "1.1 points",
"interval": "-0.1 to 2.6",
"trial_title": "Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=228",
"request_id": "u2lHWVCe-L4-C8sz"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant